Evidence map›Paper›PMID 29511553›Full record

ArticleUnited European gastroenterology journal2018

Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease.

Martha M Kirstein, Torsten Voigtländer, Nora Schweitzer, Jan B Hinrichs, Jens Marquardt, Marcus-Alexander Wörns, Roman Kloeckner, Thorben W Fründt, Harald Ittrich, Frank Wacker and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Treatment strategies for locally advanced hepatocellular carcinoma.Translational gastroenterology and hepatology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Martha M KirsteinDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Torsten VoigtländerDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Nora SchweitzerDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Jan B HinrichsDepartment of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
Jens MarquardtDepartment of Internal Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Marcus-Alexander WörnsDepartment of Internal Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Roman KloecknerDepartment of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg, Mainz, Germany.
Thorben W FründtDepartment of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Harald IttrichDepartment for Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Frank WackerDepartment of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
Thomas RodtDepartment of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
Michael P MannsDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Henning WegeDepartment of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Arndt WeinmannDepartment of Internal Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Arndt VogelDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DEJohannes Gutenberg University Mainz · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSorafenib is the recommended treatment for advanced hepatocellular carcinoma (HCC), but transarterial chemoembolization (TACE) is performed in individual cases with limited extrahepatic spread. The aim of this study was to compare the outcome of patients with HCC and extrahepatic disease (EHD) treated with sorafenib and TACE.

methodsA total of 172 patients with HCC and EHD treated with sorafenib (

resultsPatients with liver cirrhosis, higher extrahepatic tumor burden and/or infiltration of adjacent organs/structures were significantly more often treated with sorafenib. Median overall survival (OS) was similar for sorafenib- and TACE-treated patients (7 versus 8 months,

conclusionTreatment with TACE is not inferior to treatment with sorafenib in patients with limited EHD of HCC. TACE represents an effective therapeutic option in selected patients with EHD.

Indexed as

advancedBCLCextrahepatic diseaseHepatocellular carcinomametastasessorafenibTACE

Identifiers

PMID29511553
PMCPMC5833223
OpenAlexW2708343186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.